Rise Therapeutics

Executive Summary

Rise Therapeutics is a clinical-stage biotechnology company pioneering a novel class of oral, targeted immunotherapies called Oral Immune BioModulators (OIBs). Leveraging a proprietary synthetic biology-based drug delivery platform, the company enables the oral administration of biologics designed to reprogram the immune system by directing dendritic cells to correct underlying immune dysfunction. Founded in 2018 and headquartered in Rockville, MD, Rise Therapeutics is focused on treating autoimmune diseases and cancer. Its lead program is in Phase 1 clinical development, representing a potentially transformative approach to immunotherapy that combines the convenience of oral dosing with the specificity of biologic targeting. The company's platform has the potential to address significant unmet medical needs by improving patient compliance and reducing systemic side effects compared to injectable biologics. As a private, early-stage company, Rise Therapeutics' progress hinges on successful clinical data and strategic partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead OIB candidate40% success
• Q2 2027IND filing for second pipeline candidate60% success
• H1 2027Potential partnership or licensing deal for platform technology50% success